Clinical question | Diagnostic performance non-CE | Diagnostic performance CE gold standard | Author (year) |
---|---|---|---|
Astrocytic tumor grading | AUC 0.96 (95% CI 0.84–1.0) CBF ASL | AUC 0.98 (95% CI 0.87–1.00) CBF DSC | Morana et al. (2018) |
Glioma grading | AUC 0.82 (95% CI 0.62–1.00) APTw mean, AUC 0.90 (95% CI 0.73–1.00) Cho/Cr MRS | AUC 0.65 (0.47–0.84) CE T1 | Sakata et al. (2017) |
Glioma grading | AUC 0.85–0.86 (95% CI 0.74–0.92 and 95% CI 0.75–0.94) APTw90 | AUC 0.80–0.82 (95% CI 0.64–0.89 and 0.67–0.90) nCBV90 DSC | Park et al. (2015) |
Pediatric posterior fossa grading | AUC 0.97 ADC (classification rate) DWI | AUC 0.84 CE T1 (classification rate) | Rodriguéz Gutierrez et al. (2014) |
Discriminate between CNS lymphoma and GBM | AUC 0.94 ADC DWI | Equal rate of CE T1 contrast enhancement between groups | Ko et al. (2016) |
Discriminate between CNS lymphoma and GBM | Accuracy 0.91 (95% CI 0.84–0.95) CBF ASL | Accuracy 93–95% conv MRI including CE T1 | You et al. (2018) |
Discriminate between metastases and CNS lymphoma/GBM | AUC 0.96 Lac/Cr MRS | AUC 0.97 PSRmax DSC | Vallée et al. (2018) |
Progression vs pseudoprogression in GBM | AUC 0.84 (95% CI 0.72–0.96) linear anisotropy DTI | AUC 0.77 (95% CI 0.63–0.92) rCBVmax DSC | Wang et al. (2016) |
Progression vs pseudoprogression in glial tumors and brain metastases | AUC 0.79 (95% CI 0.77–0.81) T2FLAIR | AUC 0.57 (± 0.08) CE T1 | Tiwari et al. (2016) |
Progression vs pseudoprogression in glioma | AUC 0.82 CBF ASL | AUC 0.84 nrCBV DSC | Wang et al. (2018) |
Progression vs pseudoprogression in metastases | AUC 0.94-0.95 (95% CI 0.87–0.98 and 0.88-0.98) IVIM | AUC 0.91–0.93 (95% CI 0.83–0.96 and 0.86–0.98) DSC + DWI | Kim et al. (2014) |
Progression vs pseudoprogression in GBM | AUC 0.89 APTw90 | AUC 0.77 and 0.80 CBV DSC | Park et al. (2016) |
Detection of cerebral metastasis | Sensitivity 0.80% FLAIR-EPI | Sensitivity 100% SE-T1W | Tomura et al. (2007) |